George Yu
Keine laufenden Positionen mehr
Karriereverlauf von George Yu
Ehemalige bekannte Positionen von George Yu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| MEDISUN PRECISION MEDICINE LTD. | Direktor/Vorstandsmitglied | 29.08.2012 | 19.01.2017 |
| Vorstandsvorsitzender | 29.08.2012 | 19.01.2017 | |
| Finanzdirektor/CFO | 29.08.2012 | 19.01.2017 | |
| Gründer | 29.08.2012 | 19.01.2017 | |
| Präsident | 29.08.2012 | 19.01.2017 | |
SinoBiomed, Inc.
 SinoBiomed, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are researching, developing, testing and evaluating proposed new pharmaceutical products. Other activity includes developing cosmetic products. | Direktor/Vorstandsmitglied | 04.02.2011 | 04.08.2011 |
| Finanzdirektor/CFO | 16.06.2011 | 04.08.2011 | |
| Präsident | 03.09.2010 | 16.06.2011 | |
| LOGIQ, INC. | Direktor/Vorstandsmitglied | 01.03.2012 | - |
| Finanzdirektor/CFO | 01.03.2012 | 20.12.2012 | |
| Präsident | 01.03.2012 | 20.12.2012 |
Ausbildung von George Yu
| Eberhard Karls Universität Tübingen | Doctorate Degree |
| Columbia Business School | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 3 |
| China | 2 |
| Deutschland | 2 |
Operativ
| Director/Board Member | 3 |
| Director of Finance/CFO | 3 |
| President | 3 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Technology Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| LOGIQ, INC. | Technology Services |
| Private Unternehmen | 2 |
|---|---|
SinoBiomed, Inc.
SinoBiomed, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are researching, developing, testing and evaluating proposed new pharmaceutical products. Other activity includes developing cosmetic products. | Health Technology |
Medisun Precision Medicine Ltd.
 Medisun Precision Medicine Ltd. BiotechnologyHealth Technology Medisun Precision Medicine Ltd. is a biotechnology company, which focuses on developing novel neurological therapies to be directly delivered into specific regions of the brain. It portfolio includes ACX-31 program to deliver two chemotherapy drugs, temozolomide in combination with BCNU, locally to brain tumor sites. The company was founded on August 29, 2012 and is headquartered in Majuro, Marshall Islands. | Health Technology |
